Halozyme Therapeutics, Inc 8-K, filed Feb 3, 2022
Halozyme Therapeutics, Inc. (HALO)
8-K
2022-02-03
For: 2022-02-02
View Original
Added on
April 11, 2026
About this 8-K
Halozyme Therapeutics, Inc filed this 8-K on February 3, 2022, reporting on events of February 2, 2022.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________________________________
FORM 8-K
_____________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of Earliest Event Reported): | ||||||||
(Exact name of registrant as specified in its charter)
________________________
Commission File Number 001-32335
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |||||||
| (Zip Code) | ||||||||
| (Address of principal executive offices) | ||||||||
(858 ) 794-8889
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( §240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 2, 2022, Halozyme Therapeutics, Inc. (the “Company”) announced that Elaine Sun is stepping down from her position as Senior Vice President, Chief Financial Officer of the Company, effective immediately, to pursue another opportunity. The Company intends to enter into a separation agreement with Ms. Sun which we expect to provide benefits consistent with those previously disclosed by the Company on its Current Report on Form 8-K filed on December 13, 2018. The Company would like to thank Ms. Sun for her contributions during her tenure with the Company.
On February 2, 2022, Nicole LaBrosse was appointed as Senior Vice President, Chief Financial Officer of the Company, effective immediately. Ms. LaBrosse (age 39) has served as the Company’s Vice President, Finance and Accounting since January 2020. Previously she served as the Company’s Executive Director, Controller from July 2017 to December 2019 and was the Company’s Senior Director, Financial Reporting from June 2015 to June 2017. Prior to joining the Company, Ms. LaBrosse was an auditor with PricewaterhouseCoopers, LLP from 2004 to 2015. She received her B.S. degree in corporate finance and accounting and her M.S. degree in accounting from Bentley College and is a certified public accountant.
There are no family relationships between Ms. LaBrosse and any director, executive officer or person nominated or chosen by the Company to become a director or executive officer. Ms. LaBrosse does not have a direct or indirect material interest in any transaction or arrangement in which the Company is a participant.
Ms. LaBrosse’s initial annual base salary will be $485,500 and she will be eligible to participate in the Company’s executive officer incentive plans, with a 2022 bonus target equal to 45% of her base salary. Ms. LaBrosse will be eligible to receive long-term incentive awards in accordance with the Compensation Committee’s equity award grant practices for the Company’s executive officers.
Item 9.01 Financial Statements and Exhibits.
Exhibits
| Exhibit No. | Description | |||||||
Press Release of Halozyme Therapeutics, Inc. dated February 2, 2022 | ||||||||
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| HALOZYME THERAPEUTICS, INC. | ||||||||||||||
| February 3, 2022 | By: | /s/ Mark Snyder | ||||||||||||
| Name: | Mark Snyder | |||||||||||||
| Title: | Senior Vice President, General Counsel and Corporate Secretary | |||||||||||||
Halozyme Appoints New Chief Financial Officer
SAN DIEGO, February 2, 2022 - Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Nicole LaBrosse has been promoted to the position of senior vice president, chief financial officer, effective immediately. Ms. LaBrosse will succeed Elaine Sun, who is stepping down to pursue another opportunity.
Ms. LaBrosse brings over 18 years of public accounting and corporate finance experience to Halozyme. Ms. LaBrosse joined Halozyme in 2015 and has since held roles of growing responsibility within the Company. Most recently, Ms. LaBrosse served as Halozyme’s vice president, finance and accounting since 2020. Previously, Ms. LaBrosse held the role of executive director, controller since 2017. During her tenure with Halozyme, Ms. LaBrosse has demonstrated leadership with important corporate initiatives including capital return, accessing capital markets, corporate restructuring and transitioning to a growing, profitable company. Prior to joining Halozyme, Ms. LaBrosse was with PricewaterhouseCoopers, LLP for over 10 years supporting clients across a broad range of activities including initial public offerings, complex technical accounting and SEC reporting. Ms. LaBrosse received her M.S. in accounting from the McCallum Graduate School of Business, Bentley College. She also holds a B.S. in corporate finance and accounting from Bentley College. Ms. LaBrosse is licensed in California as a certified public accountant (CPA).
"I am pleased to welcome Nicole to the executive management team as our new chief financial officer and delighted to promote a strong internal candidate who already knows the depth and breadth of our business so well," said Dr. Helen Torley, president and chief executive officer. "Nicole has broad experience within the company and working with external advisors. She possesses the right financial and business skill set to support Halozyme’s future growth. On behalf of the Board of Directors, I want to thank Elaine for her contributions to Halozyme and wish her success in her future endeavors."
“I am honored to be appointed as chief financial officer of Halozyme at such an exciting time in the company’s growth,” said Ms. LaBrosse. “I have enjoyed working closely with our management team over the last several years and look forward to playing a bigger role in driving Halozyme’s growth and building shareholder value.”
About Halozyme
Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving
patients' lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme’s commercially-validated solution has touched more than 500,000 patient lives in post-marketing use via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs intended to deliver innovative therapies, with the potential to improve the lives of patients around the globe. Halozyme’s proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, AbbVie, Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon Therapeutics and ViiV Healthcare. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company’s partners make progress developing and commercializing their products being developed using ENHANZE®. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.
Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the Halozyme’s potential growth prospects. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including uncertainties concerning whether collaborative products are ultimately developed, approved or commercialized for the indications referred to in this press release, unexpected expenditures and costs, unexpected results or delays in development and regulatory review including any potential delays caused by the current COVID-19 global pandemic, unexpected regulatory approval requirements, unexpected adverse events or patient outcomes from being treated with the ENHANZE® co-formulated treatment referred to in this press release, and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release.
Contact:
Al Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com
ir@halozyme.com